Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. director Donald Zurbay reported a compensation-related equity grant. He acquired 22,822 shares of common stock through a grant coded as an award, with no cash price per share. These are in the form of Restricted Stock Units that vest in full one year from the grant date. After this grant, his directly held common stock position reported in the filing is 29,693 shares.
Vergis Janet S. reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Janet S. Vergis received a grant of 22,822 shares of Common Stock in the form of Restricted Stock Units. The RSUs vest in full one year from the grant date of June 3, 2026. After this award, she directly holds 67,324 shares, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
VARON LESLIE F reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Leslie F. Varon received an equity grant of 22,822 shares in the form of Restricted Stock Units (RSUs). The RSUs vest in full one year from the grant date, meaning the restrictions lapse at that time.
After this award, Varon directly holds 80,364 shares of the company’s common stock, reflecting a routine, compensation-related increase in her ownership rather than an open-market purchase.
MCKEON BRIAN P reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Brian P. McKeon reported an equity compensation award on Form 4. He received 28,887 shares of Common Stock in the form of Restricted Stock Units that were granted at no cash cost and will vest in full one year from the grant date. Following this award, he directly holds 28,887 shares reported in this filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported receiving an equity award of 22,822 shares of Common Stock in the form of Restricted Stock Units. The grant was recorded at no cash price per share and is classified as a grant or award acquisition rather than an open-market purchase or sale.
The RSUs vest in full one year from the grant date, meaning the restrictions lapse after that period. Following this award, Mazelsky’s directly held Common Stock position reported in this filing increased to 51,668.534 shares, showing his updated ownership stake as reflected in this Form 4.
HOSEIN CLYDE reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Clyde Hosein received an equity award of 22,822 shares on June 3, 2026 at no cash cost per share. A footnote explains this grant consists entirely of restricted stock units that vest in full one year from the grant date.
After this compensation-related award, Hosein holds a total of 64,075.456 common shares directly. Because this is a stock grant rather than an open-market purchase, it reflects routine director compensation rather than a discretionary share purchase.
HOLDEN BETSY D reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Betsy D. Holden received an equity grant of 22,822 shares of Common Stock in the form of Restricted Stock Units. The RSUs vest in full one year from the grant date, meaning restrictions lapse at that time. Following this award, she holds a total of 77,441.799 shares directly.
Gladden Brian T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Brian T. Gladden received an equity grant tied to the company’s common stock. The award covers 22,822 shares at a price of $0.00 per share as a compensation grant rather than a market purchase.
The footnotes state this grant consists entirely of Restricted Stock Units (RSUs) that vest in full one year from the grant date, meaning all restrictions lapse at that time if vesting conditions are met. Following this grant, Gladden’s direct holdings increase to 51,863.522 shares of common stock.
DENTSPLY SIRONA Inc. director James D. Forbes reported an acquisition of 28,887 shares of common stock through an equity grant. The grant was made at no cash cost per share and reflects a compensation-related award rather than an open-market purchase.
The award consists entirely of Restricted Stock Units that vest in full one year from the grant date, meaning restrictions lapse at that time if conditions are met. Following this grant, Forbes directly holds a total of 38,887 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Michael J. Barber reported a compensation-related equity grant on Common Stock. He acquired 22,822 shares at a stated price of $0.00 per share, bringing his direct holdings to 40,768 shares after the transaction.
According to the footnote, this grant consists entirely of Restricted Stock Units that vest in full one year from the grant date, meaning the restrictions lapse at that time if service conditions are met.